Astellas Pharma Statistics
Share Statistics
Astellas Pharma has 1.79B
shares outstanding. The number of shares has increased by -0.17%
in one year.
| Shares Outstanding | 1.79B |
| Shares Change (YoY) | -0.17% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
The latest short interest is 3.6M, so 0% of the outstanding
shares have been sold short.
| Short Interest | 3.6M |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 606.12 |
Valuation Ratios
The PE ratio is 178.21 and the forward
PE ratio is null.
Astellas Pharma's PEG ratio is
-2.16.
| PE Ratio | 178.21 |
| Forward PE | n/a |
| PS Ratio | 1.89 |
| Forward PS | n/a |
| PB Ratio | 1.9 |
| P/FCF Ratio | 33.76 |
| PEG Ratio | -2.16 |
Financial Ratio HistoryEnterprise Valuation
Astellas Pharma has an Enterprise Value (EV) of 3,707.6B.
| EV / Sales | 2.31 |
| EV / EBITDA | 19.03 |
| EV / EBIT | 21.5 |
| EV / FCF | 41.21 |
Financial Position
The company has a current ratio of 0.93,
with a Debt / Equity ratio of 0.63.
| Current Ratio | 0.93 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.63 |
| Debt / EBITDA | 5.16 |
| Debt / FCF | 11.18 |
| Interest Coverage | 2.13 |
Financial Efficiency
Return on Equity is 1.07% and Return on Invested Capital is 0.63%.
| Return on Equity | 1.07% |
| Return on Assets | 0.48% |
| Return on Invested Capital | 0.63% |
| Revenue Per Employee | $108,694,049.07 |
| Profits Per Employee | $1,155,279.92 |
| Employee Count | 14,754 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 1.18 |
Taxes
| Income Tax | 7.92B |
| Effective Tax Rate | 31.74% |
Stock Price Statistics
The stock price has increased by -3.19% in the
last 52 weeks. The beta is 0.14, so Astellas Pharma's
price volatility has been higher than the market average.
| Beta | 0.14 |
| 52-Week Price Change | -3.19% |
| 50-Day Moving Average | 9.69 |
| 200-Day Moving Average | 10.44 |
| Relative Strength Index (RSI) | 49.88 |
| Average Volume (20 Days) | 1,318 |
Income Statement
In the last 12 months, Astellas Pharma had revenue of 1,603.7B
and earned 17.05B
in profits. Earnings per share was 9.5.
| Revenue | 1,603.7B |
| Gross Profit | 1,311.2B |
| Operating Income | 25.52B |
| Net Income | 17.05B |
| EBITDA | 194.81B |
| EBIT | 36.97B |
| Earnings Per Share (EPS) | 9.5 |
Full Income StatementBalance Sheet
The company has 335.69B in cash and 1,005.7B in
debt, giving a net cash position of -670.03B.
| Cash & Cash Equivalents | 335.69B |
| Total Debt | 1,005.7B |
| Net Cash | -670.03B |
| Retained Earnings | 809.4B |
| Total Assets | 3,735.5B |
| Working Capital | -133.15B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 172.47B
and capital expenditures -82.5B, giving a free cash flow of 89.98B.
| Operating Cash Flow | 172.47B |
| Capital Expenditures | -82.5B |
| Free Cash Flow | 89.98B |
| FCF Per Share | 50.18 |
Full Cash Flow StatementMargins
Gross margin is 81.76%, with operating and profit margins of 1.59% and 1.06%.
| Gross Margin | 81.76% |
| Operating Margin | 1.59% |
| Pretax Margin | 1.56% |
| Profit Margin | 1.06% |
| EBITDA Margin | 12.15% |
| EBIT Margin | 1.59% |
| FCF Margin | 5.61% |
